Presumably, these results in our study suggest that the significant in vivo activity of the combination treatment might be due to ZOL-mediated anti-tumor effects on not only cell proliferation and induction of apoptosis but also cell adhesion, invasion, migration and VEGF production [12]. The gene discussed is VEGFA; the disease is neoplasm.